Why the study?
Most available antivirals target viral proteins, but viral RNA is emerging as a promising target due to highly structured RNA fundamental for viral replication.
Answers are grounded in this paper and cite their sources.
RNA is emerging as a promising antiviral target, with small molecules being developed to target structured RNA elements in viruses like SARS-CoV-2 and HIV.
The majority of antivirals available target viral proteins; however, RNA is emerging as a new and promising antiviral target due to the presence of highly structured RNA in viral genomes fundamental for their replication cycle. Here, we discuss methods for the identification of RNA-targeting compounds, starting from the determination of RNA structures either from purified RNA or in living cells, followed by in silico screening on RNA and phenotypic assays to evaluate viral inhibition. Moreover, we review the small molecules known to target the programmed ribosomal frameshifting element of SARS-CoV-2, the internal ribosomal entry site of different viruses, and RNA elements of HIV.
No takes yet. Share an insight, caveat, or question.
Mathez et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: